Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in hu… Read more
Finch Therapeutics Group Inc (FNCH) - Total Liabilities
Latest total liabilities as of June 2024: $31.36 Million USD
Based on the latest financial reports, Finch Therapeutics Group Inc (FNCH) has total liabilities worth $31.36 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Finch Therapeutics Group Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Finch Therapeutics Group Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Finch Therapeutics Group Inc Competitors by Total Liabilities
The table below lists competitors of Finch Therapeutics Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Frontier Energy Limited
OTCQB:FRHYF
|
USA | $2.14 Million |
|
Lunnon Metals Ltd
AU:LM8
|
Australia | AU$1.16 Million |
|
United Polyfab Gujarat Limited
NSE:UNITEDPOLY
|
India | ₹1.49 Billion |
|
DMCC SPECIALITY CHEMICALS LIMITED
NSE:DMCC
|
India | ₹1.41 Billion |
|
Neofect Co.Ltd
KQ:290660
|
Korea | ₩42.44 Billion |
|
Tridomain Performance Materials PT
JK:TDPM
|
Indonesia | Rp128.03 Million |
|
AV Tech Corp
TW:8072
|
Taiwan | NT$241.48 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Finch Therapeutics Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Finch Therapeutics Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Finch Therapeutics Group Inc (2019–2024)
The table below shows the annual total liabilities of Finch Therapeutics Group Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $40.67 Million | +25.19% |
| 2023-12-31 | $32.49 Million | -51.68% |
| 2022-12-31 | $67.23 Million | +190.46% |
| 2021-12-31 | $23.14 Million | -91.13% |
| 2020-12-31 | $261.06 Million | +60.05% |
| 2019-12-31 | $163.10 Million | -- |